Second Sight Medical Products (EYES) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Second Sight Medical Products (EYES) Releases Quarterly  Earnings Results, Misses Estimates By $0.04 EPS

Second Sight Medical Products (NASDAQ:EYES) issued its quarterly earnings data on Wednesday. The medical device company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.04), Morningstar.com reports. Second Sight Medical Products had a negative return on equity of 809.08% and a negative net margin of 508.90%. The company had revenue of $1.13 million for the quarter, compared to analyst estimates of $1.70 million.

EYES stock traded down $0.03 during midday trading on Thursday, hitting $0.93. The stock had a trading volume of 1,945 shares, compared to its average volume of 337,900. The stock has a market capitalization of $117.90 million, a P/E ratio of -1.85 and a beta of 2.30. Second Sight Medical Products has a 12-month low of $0.63 and a 12-month high of $2.25.

An institutional investor recently bought a new position in Second Sight Medical Products stock. Wiley BROS. Aintree Capital LLC bought a new position in Second Sight Medical Products Inc (NASDAQ:EYES) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 51,961 shares of the medical device company’s stock, valued at approximately $41,000. 6.18% of the stock is owned by institutional investors.

Several research firms have commented on EYES. Zacks Investment Research cut shares of Second Sight Medical Products from a “buy” rating to a “hold” rating in a research note on Tuesday. ValuEngine cut shares of Second Sight Medical Products from a “hold” rating to a “sell” rating in a research note on Tuesday.

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. It focuses on developing new technologies to treat the population of sight-impaired individuals. The company is developing the Orion Visual Cortical Prosthesis, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, or forms of cancer and trauma.

See Also: What is the float in trading stocks?

Related posts

Leave a Comment